Literature DB >> 21150586

Acute respiratory distress syndrome definition: do we need a change?

Jesús Villar1, Jesús Blanco, Robert M Kacmarek.   

Abstract

PURPOSE OF REVIEW: Since the first description of the acute respiratory distress syndrome (ARDS) in 1967, no specific clinical sign or diagnostic test has yet been described that identifies ARDS. Its diagnosis is based on a combination of clinical, hemodynamic, and oxygenation criteria. The purpose of this review is to examine the current definition for ARDS and to discuss why this definition may not be the most appropriate definition for this syndrome. RECENT
FINDINGS: We will briefly review our current understanding of ARDS, discuss the problems with its current diagnosis, and present clinical, pathological, and biochemical evidences supporting a more appropriate definition for ARDS. In addition, we will discuss recent efforts to identify biological markers for lung injury in pulmonary edema fluid and blood collected from critically ill patients.
SUMMARY: On the basis of current evidence, it is time for a change in the ARDS definition. A newer classification system that recognizes different severities of pulmonary dysfunction is needed. Such a system should be able to identify patients that would be most responsive to supportive therapies and those unlikely to benefit because of the severity of their disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21150586     DOI: 10.1097/MCC.0b013e32834271fb

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  9 in total

1.  95-year-old woman with sudden-onset dyspnea.

Authors:  Muaz M Abudiab; Olufunso W Odunukan; William K Freeman
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

2.  Definition of ALI/ARDS.

Authors:  Krishnan Raghavendran; Lena M Napolitano
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

3.  The APPS: an outcome score for the acute respiratory distress syndrome.

Authors:  Jesús Villar; Robert M Kacmarek
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 4.  Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise.

Authors:  M Isabel García-Laorden; José A Lorente; Carlos Flores; Arthur S Slutsky; Jesús Villar
Journal:  Ann Transl Med       Date:  2017-07

5.  The expression of HSPs, anti-oxidants, and cytokines in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome.

Authors:  Eun Joo Lee; Ji-Youn Lim; Sang Yeub Lee; Seung Hyeon Lee; Kwang Ho In; Se Hwa Yoo; Donggeun Sul; Sanghoon Park
Journal:  Clin Biochem       Date:  2012-01-31       Impact factor: 3.281

6.  High-Flow Nasal Oxygen for Severe Hypoxemia: Oxygenation Response and Outcome in Patients with COVID-19.

Authors:  V Marco Ranieri; Tommaso Tonetti; Paolo Navalesi; Stefano Nava; Massimo Antonelli; Antonio Pesenti; Giacomo Grasselli; Domenico Luca Grieco; Luca Salvatore Menga; Lara Pisani; Annalisa Boscolo; Nicolò Sella; Laura Pasin; Chiara Mega; Giacinto Pizzilli; Alessio Dell'Olio; Roberto Dongilli; Paola Rucci; Arthur S Slutsky
Journal:  Am J Respir Crit Care Med       Date:  2022-02-15       Impact factor: 30.528

7.  Dexamethasone for the treatment of acute respiratory distress syndrome: A systematic review and meta-analysis.

Authors:  Long-Hua Feng; Xiao-Dan Li; Xiao-Yu Zhang; Peng-Jiang Cheng; Zheng-Yun Feng
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

Review 8.  Clinical review: Acute respiratory distress syndrome - clinical ventilator management and adjunct therapy.

Authors:  Jonathan A Silversides; Niall D Ferguson
Journal:  Crit Care       Date:  2013-04-29       Impact factor: 9.097

9.  Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial.

Authors:  Jesús Villar; Javier Belda; José Manuel Añón; Jesús Blanco; Lina Pérez-Méndez; Carlos Ferrando; Domingo Martínez; Juan Alfonso Soler; Alfonso Ambrós; Tomás Muñoz; Rosana Rivas; Ruth Corpas; Francisco J Díaz-Dominguez; Marina Soro; Miguel Angel García-Bello; Rosa Lidia Fernández; Robert M Kacmarek
Journal:  Trials       Date:  2016-07-22       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.